Effect of a Dietary Supplement on Hip and Spine BMD: A Randomized, Doubleblind, Placebocontrolled Trial: 1515: Board #5 May 30 2:00 PM 3:30 PM

Tucker, Larry A. FACSM; Nokes, Neil; Adams, Troy

Medicine & Science in Sports & Exercise: May 2007 - Volume 39 - Issue 5 - p S230
doi: 10.1249/01.mss.0000273874.34214.2e
B-19 Free Communication/Poster - Bone Health: MAY 30, 2007 1:00 PM - 6:00 PM ROOM: Hall E

1Brigham Young University, Provo, UT.

2Rocky Mountain University of Health Professions, Provo, UT.

Email: tucker@byu.edu

Many supplements are aimed at increasing bone health, but few have been systematically evaluated using rigorous investigations.

PURPOSE: Determine the effects of two different doses of a microcrystalline hydroxyapatite-based dietary supplement called the Bone Builder®, on the bone mineral density (BMD) of women at the hip and spine compared to women taking a placebo.

METHODS: A randomized, double-blind, placebo-controlled experiment was conducted using 114 women evaluated at baseline, 6-months, and 9-months. In addition to microcrystalline hydroxyapatite, the supplement included calcium, phosporus, vitamins D and K, and other ingredients. There were two supplement dosage groups. The high-dose group received twice the supplement of the low-dose group. A control group received a placebo. BMD was measured at the hip and spine using dual energy x-ray absorptiometry (DXA), and an electronic scale was employed to measure body weight over time. Subjects were required to keep a written log of their daily supplement or placebo use to track compliance.

RESULTS: Compared to subjects taking the placebo, women in the high-dose group lost significantly less BMD at the hip at 6 months (F=4.5, p=0.03) and 9 months (F=3.8, p=0.05). Additionally, women in the high- and low-dose groups lost significantly less BMD in the inter-trochanteric region of the hip compared to placebo users at 6 months (F=7.7, p=0.01) and 9 months (F=7.9, p=0.01). At 9 months, women in the high-dose group also showed significantly greater BMD at the femoral neck than controls (F=4.7, p=0.03). Moreover, differences in BMD at the spine were significant at the trend level in favor of the high-dose group over the placebo group after 9 months of supplement use (F=2.68, p=0.10).

CONCLUSIONS: The Bone Builder® supplement (TriVita, Inc., Scottsdale, AZ) resulted in significantly greater BMD for three of the four measurements taken at the hip, including the total hip, femoral neck, and inter-trochanteric region, than placebo use after 9 months of daily use. Also, of the four BMD assessments at the hip, significant differences were evident in two after 6 months of supplement use. Apparently, the supplement is effective in improving BMD at the hip compared to placebo use in women, which should result in reduced risk of osteoporosis and fewer hip fractures over time.

© 2007 American College of Sports Medicine